Table 7Ten year incremental cost effectiveness ratios (antibiotics versus no antibiotics)

Excluding estimated costs and potential benefits of future antibiotic prophylaxis. (Base case)

Antibiotic strategyCosts per personQALYs per personIncremental cost effectiveness ratio (versus no antibiotics)
No antibiotic£6737.53409NA
Oral amoxicillin (strategy 1)£6747.53410£204,167
Oral clindamycin (strategy 2)£6797.53410£1,276,523
IV amoxicillin then oral amoxicillin (strategy 3)£6757.53410£415,498
Oral amoxicillin before and after (strategy 4)£6757.53410£416,454
IV amoxicillin, IV gent then oral amoxicillin (strategy 5a)£8597.53410£41,562,056
IV amoxicillin, IV gent then oral amoxicillin (strategy 5b)£6797.53410£1,399,481
IV vanco and IV gent (strategy 6)£7017.53410£6,367,687
IV teicoplanin and IV gent (strategy 7)£7317.53410£12,897,453
IV clindamycin (strategy 8)£6877.53410£3,104,478

From: 6.6 Appendix 6, De novo economic analysis

Cover of Prophylaxis Against Infective Endocarditis
Prophylaxis Against Infective Endocarditis: Antimicrobial Prophylaxis Against Infective Endocarditis in Adults and Children Undergoing Interventional Procedures [Internet].
NICE Clinical Guidelines, No. 64.
Centre for Clinical Practice at NICE (UK).
Copyright © 2008, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of the Institute.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.